Our third SF Pulse Issue is out!
SF Pulse is a bi-monthly newsletter that aims to elevate important issues and relevant stories shaping the ongoing fight against substandard and falsified medical products (SFs).
The newest issue includes 7 important updates across many topics including:
- A blog post from a financial company’s senior employee where he emphasizes the necessity of cross-sector collaboration against substandard and falsified medicines and the harm SFs have against all industries.
- A fascinating interview with the CEO of a leading track and trace technology provider and his take on the increasing regulations in the Asia Pacific area.
- FTFA’s white paper highlights the key enablers in the complex issue of substandard and falsified medicines, exploring areas in prevention, detection, and global and local responses.
- An article on the many factors driving the demand for counterfeit medicines like high prices, drug shortages, trade barriers, and the ease online pharmacies pose.
- An in-depth look at counterfeit weight loss drugs and the additional issue of drug compounding which is leading to many quality control issues.
- An overview of the most prominent emerging innovations aiming to improve supply chain traceability for counterfeit medicines.
- A counter-argument against the DEA’s assessment, which blames the fentanyl crisis mainly on cartels instead of recognizing the complexity of the fentanyl industry.
Did any story catch your interest? Read the full issue here: https://bit.ly/46JCzlL
